As of November 6, 2026, Repligen Corp. is a publicly traded company (Nasdaq: RGEN); its largest reported holder is Fidelity (FMR), with 13% on Schedule 13G/A of October 7, 2026, then Vanguard (5%). The largest insider holding is Karen A. Dawes, a director, with 92,816 shares (0.15% of shares outstanding), per Form 4 of May 18, 2026 (Schedule 13G/A, October 7, 2026).
Is this your company?
About to sign with, pay or invest in Repligen Corp.? See the free Snapshot first.
Free to see. No signup.
Is Repligen Corp. a real, registered company?
- Repligen Corp files with the SEC under CIK 730272 (its SEC filings).
- Its shares are listed under the ticker RGEN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under REPLIGEN CORP in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-10-07).
Who are Repligen Corp.'s owners and officers?
Repligen Corp.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-10-07).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-07 | Fmr LLC | 13% |
| Schedule 13G/A, 2026-08-14 | T. Rowe Price Associates, Inc. | 3.1% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | T. Rowe Price Associates, Inc. | 8.2% |
| Schedule 13G/A, 2026-02-13 | Roy T. Eddleman Living Trust | 4.81% |
| Schedule 13G, 2026-02-05 | Fmr LLC | 5.1% |
| Schedule 13G/A, 2025-09-08 | T. Rowe Price Associates, Inc. | 6.1% |
Questions about who owns Repligen Corp.
Who owns Repligen Corp.?
On this page, 2 holders' latest ownership filings report 5% or more of Repligen Corp.: Fmr LLC (13%, Schedule 13G/A, filed 2026-10-07) and Vanguard Capital Management (5%, Schedule 13G, filed 2026-07-31).
Who are the largest shareholders of Repligen Corp.?
By the share each holder's latest filing reports, the largest holders of Repligen Corp. on this page are Fmr LLC (13%) and Vanguard Capital Management (5%).
When did Fmr LLC buy into Repligen Corp.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-02-05, reporting 5.1%; its latest, Schedule 13G/A filed 2026-10-07, reports 13%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Repligen Corp.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Repligen Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Repligen Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Repligen Corp. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 92,816 shares (0.15% of shares outstanding) (Form 4, 2026-05-18).
- , a director: 89,062 shares (0.14% of shares outstanding) (Form 4, 2026-03-03).
- , the chief executive and a director: 45,788 shares (0.07% of shares outstanding) (Form 4, 2026-10-06).
- , a director: 40,051 shares (0.06% of shares outstanding) (Form 4, 2026-05-18).
- , the chief operating officer: 25,423 shares (0.04% of shares outstanding) (Form 4, 2026-03-23).
Shares outstanding: 63,923,738 as of 2026-10-23, from the company's latest SEC cover page.
How much has Repligen Corp. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-10-06).
Keep reading
More on Repligen Corp. and the records around it.
Companies that share a holder
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/repligen